- Details
- Description
Carfilzomib is a proteasome inhibitor and targeted anticancer medicine used primarily in the treatment of multiple myeloma. It works by inhibiting the proteasome, a cellular protein-degradation system, which can lead to the accumulation of proteins within malignant plasma cells and ultimately inhibit their growth and survival.
Indications: Carfilzomib is used in certain treatment regimens for adults with multiple myeloma, including patients who have received prior therapies. It may be administered alone or in combination with other anticancer medicines, depending on the approved treatment regimen.
Dosage form: Powder or lyophilized cake for preparation of a solution for intravenous infusion.
Administration: Administered intravenously by a qualified healthcare professional. The dosage and infusion schedule depend on the treatment regimen and the patient's clinical condition.
Possible adverse effects: May include fatigue, nausea, anemia, thrombocytopenia, neutropenia, diarrhea, fever, and shortness of breath. Serious risks can include cardiac complications, hypertension, kidney problems, infusion-related reactions, and tumor lysis syndrome.
Important: Carfilzomib is a prescription oncology medicine and should be administered under appropriate medical supervision with monitoring of blood counts, kidney function, cardiovascular status, and other relevant parameters.
